HK1118556A1 - 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives - Google Patents

5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Info

Publication number
HK1118556A1
HK1118556A1 HK08112536.8A HK08112536A HK1118556A1 HK 1118556 A1 HK1118556 A1 HK 1118556A1 HK 08112536 A HK08112536 A HK 08112536A HK 1118556 A1 HK1118556 A1 HK 1118556A1
Authority
HK
Hong Kong
Prior art keywords
thiazolo
amino
substituted
pyrimidine derivatives
pyrimidine
Prior art date
Application number
HK08112536.8A
Other languages
English (en)
Inventor
Gunnar Nordvall
Colin Ray
Tobias Rein
Daniel Sohn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1118556A1 publication Critical patent/HK1118556A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK08112536.8A 2005-04-06 2008-11-14 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives HK1118556A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06
PCT/SE2006/000399 WO2006107258A1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Publications (1)

Publication Number Publication Date
HK1118556A1 true HK1118556A1 (en) 2009-02-13

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112536.8A HK1118556A1 (en) 2005-04-06 2008-11-14 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Country Status (31)

Country Link
US (2) US7947693B2 (de)
EP (1) EP1869056B1 (de)
JP (1) JP5165553B2 (de)
KR (1) KR101335055B1 (de)
CN (1) CN101193897B (de)
AR (1) AR055890A1 (de)
AT (1) ATE487727T1 (de)
AU (1) AU2006231836B2 (de)
BR (1) BRPI0609738A2 (de)
CA (1) CA2604017C (de)
CY (1) CY1111316T1 (de)
DE (1) DE602006018124D1 (de)
DK (1) DK1869056T3 (de)
ES (1) ES2354450T3 (de)
HK (1) HK1118556A1 (de)
HR (1) HRP20110047T1 (de)
IL (1) IL185912A0 (de)
MX (1) MX2007012060A (de)
NO (1) NO20075603L (de)
NZ (1) NZ561460A (de)
PL (1) PL1869056T3 (de)
PT (1) PT1869056E (de)
RS (1) RS51581B (de)
RU (1) RU2419623C2 (de)
SA (1) SA06270072B1 (de)
SI (1) SI1869056T1 (de)
TW (1) TW200714605A (de)
UA (1) UA90707C2 (de)
UY (1) UY29454A1 (de)
WO (1) WO2006107258A1 (de)
ZA (1) ZA200708187B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
AU2007300749B2 (en) * 2006-09-29 2011-08-25 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3H)-amine derivatives and their use in therapy
AU2009221063B2 (en) 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1
US8461194B2 (en) 2008-03-07 2013-06-11 Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
LT2254869T (lt) 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
JO3082B1 (ar) 2011-09-13 2017-03-15 Eisai R&D Man Co Ltd مشتق بيروليدين-3- يل حمض خليك
JP5872105B2 (ja) 2013-03-12 2016-03-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン−３−イル酢酸誘導体の塩およびその結晶
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2016200939A1 (en) * 2015-06-08 2016-12-15 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
WO2024083933A1 (en) 2022-10-19 2024-04-25 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (de) 1955-01-03
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
IL96603A (en) 1989-12-13 1998-02-08 Lilly Co Eli Antibacterial glycopeptide derivativesProcess for their preparation and pharmaceutical preparations containing the same
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
EP1068212A1 (de) 1998-04-03 2001-01-17 Bristol-Myers Squibb Pharma Company Thiazolo[4,5-d]pyrimidine und pyridine als corticotropin releasing factor (crf) antagonisten
DE69936052T2 (de) 1998-05-01 2008-01-17 Eli Lilly And Co., Indianapolis N1 modifizierte glycopeptide
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
ATE255584T1 (de) * 2000-02-11 2003-12-15 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DK2526996T3 (da) * 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulering til intrakutan injektion
AU2004278276B2 (en) 2003-10-07 2007-10-18 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo(4,5-d) pyrimidines, useful as chemokine receptor antagonists, esp. CX3CR1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
AU2006231836B2 (en) 2010-07-15
WO2006107258A1 (en) 2006-10-12
NZ561460A (en) 2010-12-24
CN101193897A (zh) 2008-06-04
IL185912A0 (en) 2008-01-06
ATE487727T1 (de) 2010-11-15
US9440992B2 (en) 2016-09-13
ES2354450T3 (es) 2011-03-15
US20080214578A1 (en) 2008-09-04
CA2604017C (en) 2012-03-06
BRPI0609738A2 (pt) 2011-10-18
RU2007140551A (ru) 2009-05-20
SI1869056T1 (sl) 2011-02-28
AU2006231836A1 (en) 2006-10-12
PT1869056E (pt) 2011-01-13
EP1869056A1 (de) 2007-12-26
EP1869056B1 (de) 2010-11-10
DE602006018124D1 (de) 2010-12-23
AR055890A1 (es) 2007-09-12
UA90707C2 (en) 2010-05-25
PL1869056T3 (pl) 2011-04-29
NO20075603L (no) 2008-01-04
US20110092519A1 (en) 2011-04-21
CN101193897B (zh) 2010-12-01
RU2419623C2 (ru) 2011-05-27
RS51581B (en) 2011-08-31
UY29454A1 (es) 2006-11-30
JP5165553B2 (ja) 2013-03-21
HRP20110047T1 (hr) 2011-03-31
MX2007012060A (es) 2007-12-13
US7947693B2 (en) 2011-05-24
SA06270072B1 (ar) 2009-02-07
TW200714605A (en) 2007-04-16
ZA200708187B (en) 2008-11-26
CY1111316T1 (el) 2015-08-05
KR20080004483A (ko) 2008-01-09
JP2008535835A (ja) 2008-09-04
KR101335055B1 (ko) 2013-12-02
EP1869056A4 (de) 2010-02-17
DK1869056T3 (da) 2011-02-07
CA2604017A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
HK1118556A1 (en) 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
AP2008004486A0 (en) Pyrimidine derivatives
GB0525080D0 (en) Pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
IL181386A0 (en) Pyrimidine derivatives
IL192236A0 (en) Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
HK1104553A1 (en) Pyrimidine derivatives
EP1724267A4 (de) Pyrimidinderivat
GB0415364D0 (en) Pyrimidine derivatives
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
GB0525081D0 (en) Pyrimidine derivatives
IL185913A0 (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives
PL1957492T3 (pl) Podstawione bicykliczne pochodne pirymidonu
HRP20130533T1 (en) Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide
IL196107A0 (en) PRODRUGS OF-5-AMINO-3-(3'-DEOXY-??-D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE
IL172848A0 (en) 2-substituted pyrimidines
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
IL190989A0 (en) Thiazolo [4,5-c]pyridine derivatives
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
IL172845A0 (en) 2-substituted pyrimidines
TWI372760B (en) A pyrazolo[1,5-a]pyrimidine compound
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150403